探索肝素对抗AGE诱导的内皮损伤的保护机制
Junfeng Shi1,2, Yudong Guan3, Hongwei Song1,2
1Department of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
iScience
|November 4, 2024
概括
肝素通过抑制炎症和促进细胞生长,有效地保护糖尿病中晚期糖化终产物 (AGEs) 诱导的内皮损伤. 这项研究强调了肝素的作用.
科学领域:
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 先进的糖化终产物 (AGEs) 有助于糖尿病患者的内皮损伤.
- 肝素是一种抗凝剂,具有多种治疗性质.
- 肝素在减轻AGE诱导的内皮损伤中的作用需要研究.
研究的目的:
- 为了研究肝素对AGE诱导的内皮损伤的保护作用.
- 阐明肝素作用背后的分子机制.
- 为了探索肝素在糖尿病并发症中的治疗潜力.
主要方法:
- 在体外实验中评估肝素对AGE治疗的内皮细胞的影响.
- 对AGE-RAGE-NFκB信号通路的分析.
- 蛋白质组分析和基因淘汰研究以确定关键介质 (例如,LYAR).
- 在使用糖尿病小鼠模型进行体内验证.
主要成果:
- 肝素显著减轻了AGE诱导的内皮损伤,并表现出修复性作用.
- 氨酸抑制了AGE-RAGE-NFκB轴,减少了炎症反应.
- 肝素对LYAR表达的升调与增强细胞生长和减少病理损伤有关.
- 在体内研究证实了肝素对糖尿病小鼠内皮组织的保护作用.
结论:
- 氨酸在改善AGE诱导的内皮损伤方面显示出显著的潜力.
- 肝素的机制包括抑制AGE-RAGE-NFκB通路,并上调LYAR.
- 这些发现表明,在治疗糖尿病及其血管并发症方面,肝素的治疗应用范围扩大了.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
624
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
624
Formation of the Platelet Plug
4.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.6K
Introduction to Hemostasis
5.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.9K
Extrinsic and Intrinsic Pathways of Hemostasis
5.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.8K
Clot Retraction and Fibrinolysis
4.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


